Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 5.21% |
| CYNOSURE INC | CYNO | 4.42% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOT VAC | VAC | 3.27% |
| BLOOMIN' | BLMN | 2.93% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
MWI Veterinary Supply’s (MWIV - Analyst Report) third quarter 2012EPS came in at $1.15, surpassing the Zacks Consensus Estimate of $1.06 and increased 26.4% year over year. The company reported a robust 35% increase in revenues to $554.7 million and comfortably surpassed the Zacks Consensus Estimate of $514 million.
Excluding the acquisition of Micro Beef Technologies (acquired on October 31 2011), the company's organic revenue grew 18.5% in the U.S. Revenues from Micro Beef acquisition were $69.1 million for the quarter, flat sequentially.In the UK, revenue increased 16.7% year over year, including 20.2% organic growth, partially offset by a 3.5% decline related to foreign exchange.
Commissions plunged 29.6% year over year at $4.6 million, negatively impacted by the loss of a pet food line in fiscal 2012 along with a shift in commission terms for some parasiticides. Moreover, commission was high in the year-ago quarter, as the company earned a commission incentive from one of its vendors.
In the reported quarter, Internet sales to independent veterinary practices and producers in the US rose 33% year over year. Veterinary pharmacy programs revenues increased roughly 34% to $46.0 million.
Gross profit increased 28.5% to $69.5 million during the quarter. However, gross margin contracted 70 basis points (bps) year over year to 12.5%. The decline was due to lower product margins and decrease in commissions partially offset by improved freight as a percentage of total revenue.
In the reported quarter, MWI Vet’s operating income increased 24.5% to $23.4 million. However, with a 30.6% rise in selling, general and administrative (SG&A) expenses to $44.0 million, operating margin dipped 36 bps to 4.61% during the quarter.
The huge increase in SG&A expenses was based on the addition of Micro Beef and the added support for the company’s revenue growth. However, SG&A expenses, as a percentage of sales, dropped 30 bps to 7.9% during the reported quarter.
MWIV exited the quarter with cash balance of $434,000 compared with $606,000 at the end of fiscal 2011. On June 30, 2012, the company had $56.2 million on its credit facilities compared with $53.3 million at the end of September 30, 2011. The increase in outstanding on credit facility was primarily the result of the acquisition of Micro Beef assets.
Outlook
MWIV raised its guidance for fiscal 2012. The company expects to report revenues of $2.05–$2.065 billion (earlier guidance was $2.0–$2.025 billion), representing annualized growth of 31−32% (28−29%).
The company also expects EPS to be in the range of $4.14– $4.20 ($3.96– $4.06) with annualized growth of 22−24% (16−19%) in 2012. The company’s guidance is higher than the current Zacks Consensus estimates for revenue and EPS of $2.033 billion and $4.07, respectively.
Our Take
We are encouraged with MWI Vet’s better-than-expected third quarter result, guidance revision with the growth momentum maintained by the company over the past few years.
The company, which is one of the leading distributors of animal health products to veterinarians across the US, has acquired many companies to either expand its presence in areas where it has low market share or for increasing its focus in new areas.
The company has witnessed substantial market share gain amid a low-growth environment. However, the company faces stiff competition from key player like Henry Schein (HSIC - Snapshot Report), among others.
Presently, MWI Vet retains a short-term Zacks #2 Rank (Buy). However, over the long term, we have a Neutral recommendation on the stock.
Read the full reports :
Analyst Report on MWIV
Snapshot Report on HSIC